¼¼°èÀÇ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå
Cholesterol Testing
»óǰÄÚµå : 1513926
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 273 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,260,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,780,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÄÝ·¹½ºÅ×·Ñ °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 317¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 233¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÄÝ·¹½ºÅ×·Ñ °Ë»ç ¼¼°è ½ÃÀåÀº 2023-2030³â°£ CAGR 4.5%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 317¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Áø´Ü¼¾ÅÍ ÃÖÁ¾ »ç¿ëÀº CAGR 5.7%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§ 116¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÇ»ç/°ø±ÞÀÚ/º´¿ø ÃÖÁ¾ ¿ëµµ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 67¾ï ´Þ·¯, Áß±¹Àº CAGR 7.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀåÀº 2023³â 67¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 59¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 7.8%ÀÔ´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.4%¿Í 5.2%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÄÝ·¹½ºÅ×·Ñ °Ë»ç´Â ¿¹¹æ °Ç°­ °ü¸®ÀÇ Áß¿äÇÑ ¿ä¼ÒÀ̸ç, Ç÷Áß ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡¿Í Æ®¸®±Û¸®¼¼¸®µå ¼öÄ¡¸¦ ÃøÁ¤ÇÏ¿© °³ÀÎÀÇ ½ÉÀå Áúȯ À§ÇèÀ» Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÄÝ·¹½ºÅ×·Ñ °Ë»ç ¼ö¿ä´Â ½Ä»ýȰÀÇ È¥¶õ, ¿îµ¿ ºÎÁ·, Èí¿¬ µîÀÇ »ýȰ ½À°üÀÌ ¿µÇâÀ» ¹ÌÄ¡´Â ½ÉÇ÷°ü°è Áúȯ(CVD) ¼¼°èÀÇ ÀÌȯÀ² Áõ°¡¸¦ ¹è°æÀ¸·Î È®´ëÇϰí ÀÖ½À´Ï´Ù. ÄÝ·¹½ºÅ×·Ñ °Ë»ç¸¦ ÅëÇÑ Á¶±â ¹ß°ßÀº ½É°¢ÇÑ ½ÉÀå ÁúȯÀ» ¿¹¹æÇϱâ À§ÇØ Àû½Ã¿¡ °³ÀÔÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. °Ç°­ Ä·ÆäÀΰú ÀÌ´Ï¼ÅÆ¼ºêÀÇ ÃßÁøÀ¸·Î ÀÏ¹Ý ½Ã¹ÎÀÇ Àǽİú ±³À°ÀÌ Áõ°¡ÇÏ°í º¸´Ù ¸¹Àº »ç¶÷µéÀÌ ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡¸¦ ¸ð´ÏÅ͸µÇÏ´Â Á߿伺À» ÀνÄÇϰí Á¤±âÀûÀÎ °Ç°­ Áø´Ü¿¡ Àû±ØÀûÀ¸·Î Âü¿©Çϰí ÀÖ½À´Ï´Ù.

ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀåÀº °Ë»çÀÇ ÆíÀǼº°ú Á¤¹Ðµµ¸¦ ³ôÀÌ´Â ±â¼úÀÇ Áøº¸, µðÁöÅÐ °Ç°­ Ç÷§Æû°úÀÇ ÅëÇÕ, ¼ºÀÎÀÇ Á¤±âÀûÀÎ ½ºÅ©¸®´×À» ±ÇÀåÇÏ´Â Á¤ºÎ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀº °³ÀÎÀÌ Áý¿¡¼­ ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡¸¦ ¸ð´ÏÅ͸µ ÇÒ ¼öÀÖ´Â ÈÞ´ë¿ë, »ç¿ëÀÚ Ä£È­Àû ÀÎ ÀåÄ¡¸¦ °³¹ßÇÏ¿© °Ç°­ °ü¸®¸¦ ÀÚÁÖ Ã£´Â Çʿ伺À» ÁÙÀÔ´Ï´Ù. °Ô´Ù°¡, ÄÝ·¹½ºÅ×·Ñ °Ë»ç¿Í µðÁöÅÐ ÀÇ·á ±â·ÏÀÇ ÅëÇÕÀº ȯÀÚ µ¥ÀÌÅÍÀÇ °ü¸®¿Í ÃßÀûÀ» °­È­ÇÏ°í °³º°È­µÈ Àû½Ã °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÄÝ·¹½ºÅ×·Ñ °Ë»ç¿Í µðÁöÅÐ Â÷Æ®ÀÇ ÅëÇÕÀº ȯÀÚ µ¥ÀÌÅÍÀÇ °ü¸® ¹× ÃßÀûÀ» °­È­ÇÏ¿© ȯÀÚ °¢ÀÚ¿¡°Ô ¸Â´Â Àû½Ã Äɾ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

POC(Point of Care)ÀÇ µ¿ÇâÀÌ È®´ëµÇ°í ÀÖ¾î ÀÇ·á Á¦°ø¾÷ü¿Í ȯÀÚ°¡ Ä¡·á¹ý¿¡ ´ëÇØ Àû½Ã¿¡ Åä·ÐÇÏ´Â °ÍÀ» ÃËÁøÇÏ´Â °á°ú¸¦ Áï½Ã Á¦°øÇÕ´Ï´Ù. ÀÌ µ¿ÇâÀº Áö¿ª ÀÇ·á ÇöÀå°ú ¾à±¹¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¶ÇÇÑ °³ÀÎ °Ç°­ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ÒºñÀÚ ÁÖµµÀÇ ¿òÁ÷ÀÓÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, ½ÃÆÇµÇ´Â ÄÝ·¹½ºÅ×·Ñ °Ë»ç ŰƮ¿Í ¿þ¾î·¯ºí °Ç°­ ±â±âÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. °í¿ëÁÖ¿Í º¸Çèȸ»ç°¡ Áö¿øÇÏ´Â ¿¹¹æ°Ç°­°ü¸® ÇÁ·Î±×·¥µµ Á÷¿øÀÇ °Ç°­¼º°ú¸¦ Çâ»ó½Ã۰í ÀáÀçÀûÀÎ °Ç°­¹®Á¦¸¦ Á¶±â¿¡ ´ëóÇÔÀ¸·Î½á ÀÇ·áºñ¸¦ Àý°¨Çϱâ À§ÇØ ÄÝ·¹½ºÅ×·Ñ °Ë»ç¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 42°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cholesterol Testing Market to Reach US$31.7 Billion by 2030

The global market for Cholesterol Testing estimated at US$23.3 Billion in the year 2023, is expected to reach US$31.7 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Diagnostic Centers End-Use, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$11.6 Billion by the end of the analysis period. Growth in the Physicians / Providers & Hospitals End-Use segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.7 Billion While China is Forecast to Grow at 7.8% CAGR

The Cholesterol Testing market in the U.S. is estimated at US$6.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.9 Billion by the year 2030 trailing a CAGR of 7.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Cholesterol Testing Market - Key Trends and Drivers Summarized

Cholesterol testing is a crucial component of preventive healthcare, enabling the assessment of an individual's risk for heart disease by measuring cholesterol and triglyceride levels in the blood. The demand for cholesterol testing is expanding, driven by the increasing global incidence of cardiovascular diseases (CVDs) influenced by lifestyle factors such as poor diet, lack of physical activity, and smoking. Early detection through cholesterol testing is essential for timely interventions to prevent severe cardiac conditions. With growing public awareness and education, facilitated by health campaigns and initiatives, more people are recognizing the importance of monitoring cholesterol levels and are proactively participating in regular health screenings.

The cholesterol testing market is experiencing growth due to several factors: technological advancements that enhance the convenience and accuracy of testing, integration with digital health platforms, and increasing government recommendations for regular screenings in adults. Technological innovations have led to the development of portable and user-friendly devices that allow individuals to monitor their cholesterol levels at home, reducing the need for frequent healthcare visits. Additionally, the integration of cholesterol testing with digital health records enhances the management and tracking of patient data, enabling personalized and timely care. This integration supports remote patient monitoring, allowing healthcare providers to consult with patients based on digitally shared test results.

The trend toward point-of-care (POC) cholesterol testing is growing, providing immediate results that facilitate timely discussions between healthcare providers and patients about treatment options. This trend is particularly beneficial in community health settings and pharmacies. Furthermore, there is a rising consumer-driven movement towards personal health monitoring, which has spurred the growth of over-the-counter cholesterol testing kits and wearable health devices. Preventive health management programs, supported by employers and insurance companies, are also incorporating cholesterol testing to improve employee health outcomes and reduce healthcare costs by addressing potential health issues early.

Select Competitors (Total 42 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â